Clinical Trial To Evaluate The Effect Of Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance

A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00241072

Enrollment

Registered

2005-10-18

Start date

2002-09-30

Completion date

2005-07-31

Last updated

2012-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Impaired Glucose Tolerance

Brief summary

THE PURPOSE OF THIS STUDY IS TO DETERMINE IF 24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG) IMPROVES INSULIN SENSITIVITY IN SUBJECTS WITH HIGHER THAN NORMAL GLUCOSE LEVELS USING A TEST CALLED THE EUGLYCEMIC CLAMP.

Interventions

DRUGvalsartan

24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

history or presenting hypertension Elevated fasting blood glucose levels -

Exclusion criteria

Pregnancy potential Diabetes mellitus Other criteria apply \-

Design outcomes

Primary

Measure	Time frame
Change from baseline insulin sensitivity after 24 weeks	—

Secondary

Measure	Time frame
Change from baseline in the function of cells that line blood vessels after 24 weeks	—
Change from baseline in markers of vascular inflammation after 24 weeks	—
Adverse events and serious adverse events at each study visit for 24 weeks	—
Hematology, blood chemistries, and urine measurements for up to 24 weeks	—
Vital signs and physical examinations for up to 24 weeks	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026